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Abstract: Nuclear spin polarization can be significantly in-
creased through the process of hyperpolarization, leading to
an increase in the sensitivity of nuclear magnetic resonance
(NMR) experiments by 4–8 orders of magnitude. Hyperpolar-
ized gases, unlike liquids and solids, can often be readily
separated and purified from the compounds used to medi-
ate the hyperpolarization processes. These pure hyperpolar-
ized gases enabled many novel MRI applications including
the visualization of void spaces, imaging of lung function,
and remote detection. Additionally, hyperpolarized gases
can be dissolved in liquids and can be used as sensitive mo-
lecular probes and reporters. This Minireview covers the fun-
damentals of the preparation of hyperpolarized gases and
focuses on selected applications of interest to biomedicine
and materials science.
1. Introduction
The use of techniques to enhance nuclear spin polarization (P)
to order unity (i.e. , nearly 100%) results in corresponding gains
in NMR sensitivity by 4–8 orders of magnitude.[1] This process
of significant polarization enhancement-well above that ach-
ieved at thermal equilibrium-is termed hyperpolarization. Hy-
perpolarization of solids, liquids, and gases[2] has been demon-
strated via a number of techniques including Brute Force Po-
larization (BFP),[3] Spin Exchange Optical Pumping (SEOP),[4] Dy-
namic Nuclear Polarization (DNP),[1c] Chemically-Induced Dy-
namic Nuclear Polarization (CIDNP)[5] photo-CIDNP,[6]
Parahydrogen Induced Polarization (PHIP),[7] and Signal Amplifi-
cation By Reversible Exchange (SABRE).[8] A wide range of
nuclei can be hyperpolarized, including 1H,[9] 3He,[10] 7Li,[11]
13C,[1c, 12] 15N,[13] 19F,[14] 31P,[15] 83Kr,[16] and 129Xe,[4, 17] among
others.[18] Hyperpolarized (HP) substances are revolutionizing
the fields of NMR spectroscopy and magnetic resonance imag-
ing (MRI), because many applications that were previously im-
practical because of weak NMR signals (e.g. , from sub-mm me-
tabolites) are now becoming possible. Moreover, the enormous
gain in attainable signal-to-noise ratio (SNR) allows spectro-
scopic detection and imaging of HP compounds to be per-
formed in seconds, obviating the need for time-consuming
signal averaging and thermal recovery of the spin magnetiza-
tion. The ability to rapidly acquire signals with very high SNR
from HP systems is the inherent feature that is greatly desira-
ble for in vivo gas imaging applications: that is, images can be
acquired during a single breath hold; sufficient signal can be
attained despite the low density of gas compared to liquid.
While liquid HP contrast agents are injected in vivo to probe
metabolism[19] (extensively discussed in many recent reviews)[20]
or used otherwise,[21] they typically cannot be used to probe
gas-phase processes in vitro or in vivo. This Minireview focuses
on the techniques allowing the production of HP gases with
particular application to their use in biomedical applications,
and explores some examples from materials science.
We begin with the fundamentals of SEOP in the context of
NMR hyperpolarization of 129Xe gas. Although other noble
gases have been hyperpolarized, none are as widely used for
magnetic resonance as HP 129Xe, which has a relatively large
natural abundance (ca. 26%) and is relatively cheap (ca. USD
20 per L). The selected applications described here include
functional lung imaging,[22] metabolic brown fat imaging,[23]
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and biosensors[24] (including those enabled by genetic encod-
ing).[25] A recent demonstration of the DNP process to hyper-
polarize 129Xe[26] and hydrocarbon gases[27] is also described.
HP gases can also be efficiently produced via PHIP, when
parahydrogen gas is added in a pairwise manner to a multiple
chemical bond (C=C or C/C) in an unsaturated molecule, re-
sulting in a gaseous HP product. This process can be per-
formed in heterogeneous fashion,[9a,28] and despite low T1 of
the HP states, this powerful scalable technique allows for
cheap preparation of HP hydrocarbons on demand. Moreover,
because protons are being directly hyperpolarized and detect-
ed, it is inexpensive and straightforward to perform (since ex-
pensive isotopic enrichment and heteroatom-specific instru-
mentation can be obviated) and thus is readily applied with
conventional clinical MRI scanners. This Minireview describes
the fundamentals of PHIP for production of HP gases,[29] select-
ed recent developments to extend the lifetime of the HP state
through the use of the long-lived spin states (LLSS),[30] and HP
gas application for void space imaging, remote sensing, time
of flight imaging, and micro-fluidic imaging.
In all cases, the separation from other compounds required
for hyperpolarization processes (e.g. , Rb in case of SEOP of HP
129Xe, free radicals in the case of DNP, and homogeneous or
heterogeneous catalysts in the case of PHIP) is readily achieva-
ble, and experiments can be performed with HP gases in
a chemically pure form.
2. Fundamentals of Noble Gas Hyper-
polarization
2.1. SEOP
The most commonly employed method for generating HP
noble gases is spin-exchange optical pumping (SEOP). The de-
velopment of SEOP is rooted in the pioneering work of Kas-
tler,[31] who was recognized with the Nobel Prize in physics for
demonstrating that electronic spin order can be created in
alkali metal vapors using circularly polarized laser light. Later
Bouchiat, Carver, and Varnum[32] showed that the addition of
3He to the gas mixture permitted helium nuclear spins to be
polarized by spin-exchange collisions with the optically
pumped alkali vapor atoms-work that was extended to 129Xe
by Grover.[33] The rich physics of SEOP has been extensively ex-
plored by Happer, Cates, Chupp, Walker, and many others
(e.g. , refs. [4, 17b,34]), ultimately leading to the ability to pro-
duce large quantities of HP noble gases with nuclear spin po-
larization levels approaching unity for use in a variety of appli-
cations-including those described throughout this Mini-Review.
The underlying phenomenon of SEOP has been reviewed ex-
tensively elsewhere,[4, 35] but can be briefly described as follows
(Figure 1): First, a heated alkali metal vapor is irradiated with
resonant circularly polarized light. Angular momentum conser-
vation results in population being driven from appropriate
spin-state ground states (e.g. , mJ=@1/2 with s+ light, ne-
glecting nuclear spin degrees of freedom). The ground-state
levels are repopulated at roughly the same rates, resulting in
depletion of one-spin state and population accumulation in
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the other-rendering the alkali metal vapor electronically spin
polarized. Gas-phase collisions then transfer polarization from
the electrons of the alkali metal to the spins of the noble gas
nuclei via Fermi-contact interactions.
This process is allowed to continue so that the nuclear spin
polarization can accumulate over time, ultimately yielding
a steady-state nuclear spin polarization given by Equation (1):
PN ¼ hPAMi ?
gSE
gSE þ GN
. -
ð1Þ
where hPAMi is the spatially averaged polarization of the alkali
metal vapor, GN is the noble gas nuclear longitudinal relaxation
rate (1/T1) in the optical pumping cell, and gSE is the spin-ex-
change rate (i.e. , the rate at which polarization can be trans-
ferred from alkali metal to the noble gas).
Although the vast majority of SEOP experiments have em-
ployed the spin I=1/2 noble gas isotopes 129Xe and 3He, the
quadrupolar species 21Ne (I=3/2),[36] 83Kr (I=9/2),[37] and
131Xe[38] (I=3/2) can also be polarized via this method. For the
alkali metal vapor, Rb is most-commonly employed for practi-
cal reasons-including its low melting point[39] (facilitating va-
porization) and the availability of high-powered lasers resonant
with its D1 transition;
[40] however, K and Cs are also utilized
(particularly for 3He[41] and 129Xe,[42] respectively).
Technological developments for SEOP have been extensively
reviewed elsewhere,[35] and only a brief description is given
here. Devices for preparing HP noble gases may be grouped
into two types: “stopped-flow” and “continuous-flow”. In
a stopped-flow device,[43] a batch of a desired gas mixture is
loaded into an OP cell (which contains a quantity of alkali
metal) and is heated and optically pumped with a laser; once
the gas is hyperpolarized, OP is stopped and the gas is trans-
ferred to the sample (usually after the cell has cooled to con-
dense the alkali metal) ; alternatively, multiple batches may be
systematically polarized and collected to accumulate the HP
gas prior to transfer. In a continuous-flow device,[44] a desired
gas mixture is allowed to flow from its source continuously
through a heated cell while it is irradiated by the laser ; the
flow rate is chosen to allow sufficient average residency of
noble gas atoms in the cell to enable the gas to be hyperpolar-
ized “on the fly”. The HP gas mixture can then either be direct-
ed into the sample or a cryo-condenser (to collect the other-
wise-dilute HP noble gas and deliver it purely and with high
density, following sublimation).[44a]
All of the noble gas isotopes are amenable to the stopped-
flow design,[38,43h,i, 45] whereas the relatively high spin-exchange
rates and facile cryo-storage of 129Xe’s polarization[46] make it
the best choice for use in a continuous-flow device. Both
device designs have evolved considerably over the years, ach-
ieving ever-greater gas polarizations and production amounts/
throughputs-benefiting in particular from the advent of com-
pact, high-power, relatively low-cost light sources embodied
by spectrally-narrowed laser diode arrays.[40,43e,g, 44f,47]
2.2. Other Methods for Hyperpolarizing Noble gases: MEOP,
“Brute Force”, and DNP
In addition to SEOP, HP noble gases can be prepared by meta-
stability exchange optical pumping (MEOP), “brute force”, and
dynamic nuclear polarization (DNP), and we briefly describe
these approaches here.
In MEOP,[48] an electrical discharge is used to create metasta-
ble (electronically excited) atoms in a dilute gas. The unpaired
electrons of these metastable atoms can be spin-polarized via
optical pumping with a laser. The angular momentum of the
electron spin may then be transferred to the nuclear spin of
another gas atom in the cell during a metastability-exchange
collision. The process is allowed to continue until a bulk nucle-
ar spin polarization develops across the cell. Finally, a pump is
used to compress the HP gas to a sufficient density prior to
use.[49] MEOP works well for 3He[48] and has been highly effec-
tive at producing clinical-scale amounts for biomedical imag-
ing experiments (e.g. , [50]) ; MEOP is generally less effective for
the heavier noble gas isotopes because of stronger relaxation
mechanisms.[51]
Figure 1. Schematic representations of SEOP.[2b, 4] (a) SEOP cell containing
a noble gas (here, Xe), buffer gases (e.g. N2), and a small quantity of vapor-
ized alkali metal (here, Rb); the cell is irradiated by circularly polarized laser
light that can be absorbed by the alkali metal atoms. (b) The first step of
SEOP: in order to conserve angular momentum, photon absorption results
in selective population depletion from one Rb ground electronic state (ne-
glecting Rb nuclear spin for simplicity). Although gas-phase collisions work
to equalize the excited-state populations (and hence, the ground-state repo-
pulation rates), continuous depletion of one state by the laser leaves the
alkali metal vapor electronically spin-polarized. (c) The second step of SEOP:
Gas-phase collisions occasionally allow spin order to be transferred from the
alkali metal atom electrons to the noble gas nuclei via Fermi contact hyper-
fine interactions, thereby hyperpolarizing the noble gas over time. Repro-
duced with permission from Ref. [2b] John Wiley & Sons, Ltd. , 2015.
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Next, to understand the so-called brute-force (BF) approach,
one should first consider the relation determining the equilibri-
um (“thermal”) nuclear spin polarization (for I=1/2 nuclei), see
Equation (2):
PeqN ¼: tanh
g(hB0
2kT
. -
ð2Þ
where g is the nuclear gyromagnetic ratio, B0 quantifies the
strength of the magnetic field, T is the absolute temperature,
(h is Planck’s constant divided by 2p, and k is Boltzmann’s con-
stant. At room temperature and in a typical superconducting
magnet, PeqN will be &10@5–10@6. Thus, if the sample tempera-
ture were lowered to milli-Kelvin temperatures (and enough
time were allowed for the nuclear spins to relax to their new
equilibrium conditions), the nuclear spin polarization would
exceed 10%. Although the approach can be time consuming,
such BF approaches have used 3He/4He dilution refrigerators to
polarize the nuclear spins in different substances, including
noble gases.[52]
Finally, noble gases can also be hyperpolarized via DNP.[53]
Here, the approach is essentially the same as that of dissolu-
tion DNP (d-DNP), introduced by Golman and co-workers in
2003.[1c] Briefly, the approach requires the substance to be hy-
perpolarized (here, 129Xe) to be mixed in a glassy frozen matrix
containing molecules with unpaired electron spins (e.g. ,
a stable radical or a photoinduced, non-persistent radical).[53c]
With the matrix placed at very low temperatures (~1 K) and at
high magnetic field (several T), the unpaired electrons obtain
a near-unity spin polarization. The matrix is then irradiated
with microwaves in order to drive the high spin polarization to
surrounding nuclei in the matrix, allowing a high bulk nuclear
spin polarization to accumulate over time. The matrix is then
rapidly warmed, sublimating the HP xenon as a pure gas-
hence the name “sublimation DNP” given for this approach.[53b]
Using DNP, polarization values of ~30% have been achieved in
~1.5 h,[53b] despite identified issues with a spin-diffusion bottle-
neck between electron and 129Xe spins.[53a] Although the
amounts and polarization values achieved thus far with DNP
are not as high as corresponding values achieved with SEOP,
the advantages are the increasing availability and general ap-
plicability of dissolution DNP polarizers in biomedical facilities-
including Oxford’s HyperSense[1c] and more recently, GE Health-
care’s SPINlab.[54]
2.3. The Rise of Magnetic Resonance Applications of Hyper-
polarized Noble Gases
Prior to finding their way into magnetic resonance, HP gases
found their first applications in fundamental physics experi-
ments (work that of course continues, see for example,
refs. [55, 56]). And although the portions of this Mini-Review
that are dedicated to HP noble gases are largely concerned
with biomedical applications of 129Xe, the first MR applications
actually involved studies of materials (as well as investigations
of the use of HP 129Xe as a source of hyperpolarization for
other spins).
Soon after the demonstration of ultra-long 129Xe relaxation
times for frozen solid xenon,[46] Pines and co-workers used HP
129Xe NMR to probe the surfaces of powdered substances[43a]
(and high-field gas-phase spectroscopy was also demonstrated
by performing SEOP within an NMR magnet).[42a] Soon after-
wards, the exquisite sensitivity of the 129Xe chemical shift was
investigated for probing surfaces of a number of porous mate-
rials and particles[57]-as was the ability to transfer the 129Xe hy-
perpolarization to the nuclear spins of other substances.[58] The
advent of continuous-flow production of HP 129Xe[44a] was soon
applied to greatly facilitate studies of materials surfaces,[59] in-
cluding under conditions of magic angle spinning.[60] Since
that work, HP xenon has been used to study diffusion in con-
fined spaces or porous media;[61–63] image such systems as
a function of gas flow[64] or 129Xe chemical shift ;[65] or spectro-
scopically probe single-crystal surfaces,[66] liquid crystals,[67] or
combustion processes.[68] However, the greatest body of mate-
rials-related work has concerned the effort to probe void
spaces and surfaces in microporous or nanoporous materials
with HP 129Xe, thereby providing information about pore size,
pore shape, and gas dynamics in: nanochanneled organic, or-
ganometallic, and peptide-based molecular materials[69] (includ-
ing in macroscopically oriented single crystals) ;[70] multi-walled
carbon nanotubes;[71] gas hydrate clathrates;[72] porous poly-
meric materials and aerogels;[73] metal-organic frameworks;[74]
calixarene-based materials and nanoparticles ;[75] organo-
clays;[76] mesoporous silicas;[77] and zeolites and related materi-
als[78]—efforts that have been aided by computational studies
of xenon in confined spaces (e.g. , ref. [79]). For a more in-
depth review of HP 129Xe in microporous and nanoporous ma-
terials, see ref. [80] .
Indeed, 129Xe has found the widest NMR/MRI application of
the HP noble gases-a fact that is at least partially due to its sig-
nificant natural abundance (26.44%) and ready recoverability
from air during oxygen production. While 3He does have the
advantage of a roughly three-fold greater gyromagnetic ratio,
its weak chemical shift dependence and lack of significant in-
teraction with other substances make it a poor probe of other
substances. More importantly, the lack of natural abundance
(most 3He comes from tritium decay) will limit the future use
of this isotope for wide-scale magnetic resonance applica-
tions.[81] The rapid relaxation suffered by the quadrupolar iso-
topes (21Ne, 83Kr, and 131Xe) presents a challenge for most
HP NMR applications, although as pointed out by Meersmann
and co-workers, the quadrupolar interaction also endows
a unique sensitivity of HP 83Kr to surface chemistry and local
geometry that can be complementary to the information pro-
vided by 129Xe chemical shift—a feature that can prove useful
for probing porous materials, lung tissues, and other sys-
tems.[37, 68b,82]
3. Clinical Application of Hyperpolarized
Xenon-129 MRI
HP xenon-129 MRI (129Xe-MRI) is an MRI modality first devel-
oped in the 1990s for enhanced lung imaging of ventilation
and perfusion and regional information on gas exchange. It
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has been used to image patients with a number of respiratory
diseases, including asthma, COPD, and pulmonary fibrosis. In
addition to its use in disease assessment and long-term man-
agement, in vivo gas-phase 129Xe-MRI has the potential to pro-
vide imaging biomarkers of drug efficacy, which could be used
to stratify treatment, improve patients’ quality of life, and cut
down healthcare costs. It can also be potentially employed by
pharmaceutical companies to speed up decision-making in
proof-of-concept studies in drug development.
3.1. From Mice to Men
Identified by British chemists William Ramsay and Morris Tra-
vers in 1898[83] (following their discovery of neon and krypton
a few months earlier), xenon is a colorless and odorless noble
gas. Xenon initially captured the attention of clinicians as
a general anesthetic agent when Albert Behnke, a US Navy
physician, investigated the cause for “drunkenness” observed
in deep-sea divers.[84] Interestingly, Behnke also happened to
be the clinician who had studied the anesthetic effects of ni-
trogen and helium in humans.[85] It was Lawrence et al.[85] who
first published experimental data on the general anesthetic ef-
fects of xenon with mice as their test subjects. It took clinicians
5 years to put xenon to use in clinical settings,[86] and xenon
has continued to be used as a general anesthetic since.
3.2. The Motivation for Hyperpolarized Xenon-129 MRI
The next major clinical application of xenon-129 came in 1994
in the form of its use as an inhalational contrast agent for
magnetic resonance imaging (MRI).[87]
Plain radiograph and computed tomography (CT) are cur-
rently the main modalities used to image the lungs in clinical
settings. Despite their ability to provide detailed anatomical
data, in particular with high resolution CT, their main draw-
backs are the risks involved with repeated radiation exposure
and the inability to provide physiological information on re-
gional lung function. Although conventional MRI has been
a game-changer in both neuro and hepatic imaging, its de-
pendence on the protons of water molecules in tissue to pro-
vide nuclear magnetic resonance (NMR) signal[87] has meant
that it is of little value in imaging the lungs due to poor image
quality because of three factors : 1- low proton abundance
within the lung parenchyma, 2- air-tissue interface causing
magnetic field heterogeneity, and 3- image degradation secon-
dary to cardiac and respiratory motion.[88]
The NMR signal strength of a given species depends on its
nuclear spin, that is, polarization, concentration, and the
volume of the element. Except for those in water and fat, the
concentrations of all other protons and nuclear species are too
low to be of use in conventional MRI. However, hyperpolariza-
tion can be used to overcome the otherwise low detection
sensitivity for low-concentration spins. For example, by deliver-
ing HP 129Xe to excised mouse lungs, Albert and colleagues
were able to obtain improved MR lung images compared to
those obtained with conventional MRI.[87]
3.3. Hyperpolarized Xenon-129 MRI—There and Back Again
HP xenon-129 MRI of human lungs, which are obviously much
larger than those of mice, proved challenging; it took physi-
cists three years following Albert’s paper in 1994 to be able to
publish data on human studies.[89] The challenge was due to
the need to produce much larger quantities of HP 129Xe and to
achieve adequate levels of polarization. Furthermore, conven-
tional MR imaging sequences had to be modified as the polari-
zation of the noble gas is non-renewable, and some polariza-
tion is lost every time an MR excitation pulse is applied.[90]
These issues led to a shift in interest from 129Xe to helium-3
(3He), a fellow noble gas, whose larger gyromagnetic ratio and
larger achievable polarization compared to 129Xe at the time al-
lowed for better signal intensity and image resolution for
a given amount of HP gas.[91]
Interest in 129Xe was reignited in the early 2010s; this resur-
gence was due to the fact that contrary to 129Xe, which is natu-
rally occurring, 3He is a byproduct of tritium decay. 3He had
become scarce as the US sequestered 3He for 3He-based neu-
tron detectors for national security, leading to extremely low
availability of 3He for scientific research and an exponential rise
in its price.[91b] As a result, it was unlikely that 3He-MRI would
become a routine imaging modality in clinical settings, and so
interest in 129Xe-MRI was rekindled.
3.4. Safety & Tolerability Profile in Patient Groups
Over the past two decades, 129Xe-MRI has been improved and
utilized in imaging a wide range of respiratory diseases, includ-
ing asthma,[92] chronic obstructive pulmonary disease
(COPD),[92b,93] cystic fibrosis (CF),[92a] and pulmonary fibrosis.[94]
Studies specifically designed to investigate the safety and tol-
erability of 129Xe-MRI have not shown major common side ef-
fects in various patient groups, including those with asth-
ma,[92a] and mild-moderate COPD,[92a, 95] with light-headedness
of very short duration as the main reported minor side effect.
3.5. Ventilation Imaging
Ventilation imaging provides valuable clinically relevant infor-
mation relevant to regional lung function. Regions with normal
ventilation typically appear bright and homogenous on 129Xe-
MRI, and in a healthy subject with normal lung function, both
lungs show relatively homogenous ventilation except for two
regions (as seen in Figure 2 and discussed in the caption). In
those with diseased lungs where regional ventilation is im-
paired, the abnormal regions will appear darker; these regions
are called “ventilation defects”.
Compared to healthy volunteers, 129Xe distribution has been
shown to be regionally heterogeneous with ventilation defects
in a number of different patient groups, including those with
asthma, COPD, and CF.[92a,93c,d] Ventilation imaging has also
been shown to correlate with spirometry[93c] and CT findings[96]
in patients with COPD.
Additionally, ventilation imaging has been used to assess
the efficacy of drug therapy. Studying the impact of Salbuta-
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mol in patients with asthma, Parragra’s group[92b] has reported
a significant reduction in ventilation defects after Salbutamol
administration.
Hence 129Xe-MR ventilation imaging, although appearing
simple, can be used to not only assess disease, but to also
assess drug efficacy and monitor disease progression.
3.6. Diffusion Imaging
The apparent diffusion coefficient (ADC) of gas within lung is
a function of alveolar size and geometry. This can be assessed
using 129Xe-MRI to characterize pulmonary microstructure at
the alveolar level, as seen in Figure 3.
129Xe-MRI derived ADC mapping has been shown to corre-
late well with pulmonary function tests,[93d,95] including total
diffusing capacity for the lung (TLco). This is of important clini-
cal significance, as it clearly illustrates the ability of 129Xe-MRI
to provide regional quantitative lung function data. In addition
to its potential use in disease diagnosis, monitoring and as-
sessing therapeutic drug efficacy, diffusion imaging can also be
used to plan surgery, including tumor resection and lung
volume reduction surgery for emphysema, as it can aid predic-
tion of post-surgery lung function. The predicted post-surgery
lung function is currently calculated using ventilation or perfu-
sion scintigraphy and quantitative CT; however, there is a risk
that scintigraphy, the most commonly used imaging modality,
may underestimate post-operative lung function,[97] thereby,
preventing the patient from undergoing potentially curative
surgery.
3.7. Dissolved Phase Imaging
129Xe (in contrast to 3He) is highly lipophilic and soluble in bio-
logical tissues and thus is able to provide information on gas
exchange and pulmonary perfusion, which can be particularly
interesting in the context of functional lung imaging.[98] It is
the associated persistent exchange of 129Xe between the gas
and dissolved compartments, each with its own different reso-
nance frequencies, that is central to assessing gas exchange
using 129Xe-MRI.[99] Therefore, combined imaging of the gas
phase 129Xe and the dissolved phase 129Xe would permit venti-
lation/perfusion (V/Q) imaging-and consequently a more direct
mapping of lung function.[87] Hence, although 129Xe-MRI initially
lagged behind 3He-MRI, developmentally, this capability pro-
vides another reason why 129Xe-MRI is likely to be the pragmat-
ic HP noble gas MRI modality of choice.
Although the majority of the inhaled 129Xe remains in the air-
spaces, where it exhibits its primary gas-phase resonance,
a portion dissolves in alveolar septa and crosses the alveolar-
capillary barrier to dissolve in the blood. The resulting shift in
the resonance frequency leads to the appearance of two addi-
tional distinct resonances: 1) the barrier resonance, and 2) the
hemoglobin-associated 129Xe resonance, as seen in Figure 4
(We note the intensity differences between the two spectra
are due primarily to the variation in the amount and speed at
which hyperpolarised xenon gas was inhaled by the two vol-
Figure 2. 129Xe-MRI of a healthy volunteer. a) Coronal plane 25 mm slice
129Xe-MR ventilation image of a healthy adult male, with 129Xe appearing
bright. The upper airways are visualized and delineated. b) Coronal plane
25 mm slice fused 129Xe-MR ventilation and proton co-registration image,
with 129Xe appearing blue-green. The two black regions pointed out in the
fused image (yellow arrows) are due to a diaphragmatic eventration and
pulmonary vasculature, clearly defined on the fused image (blue arrows). J.
Thorpe, B. Haywood, M. Barlow, S. Safavi & I. Hall—University of Nottingham
(Unpublished work).
Figure 3. ADC map of a healthy volunteer and a patient with COPD.
a) Healthy volunteer with a low mean ADC of 0.037:0.021 cm2 s@1, indicat-
ing normal alveolar microstructure. b) Patient with COPD with high ADC
values (0.068:0.028 cm2 s@1) in the parenchyma, indicating alveolar destruc-
tion. Reproduced with permission from Ref. [95] John Wiley & Sons, Ltd. ,
2011.
Figure 4. 129Xe NMR spectra recorded from two healthy volunteers. Two
dotted lines have been placed to represent the expected dissolved state
peaks, the left most line representing the expected ~196 ppm lung paren-
chyma peak, and the right most line representing the expected 216 ppm
red blood cell peak. S. Hardy, B. Haywood, M. Barlow, S. Safavi & I. Hall—Uni-
versity of Nottingham (Unpublished work).
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unteers. As volunteers became more familiar with the breath-
ing protocol, the improvements in both ventilatory image
quality and dissolved phase signal/noise were noted). This
transfer pathway is identical to that followed by oxygen; there-
fore, in addition to being a ventilation probe, 129Xe is also
a gas diffusion transfer probe.[94a]
The signal intensity of the dissolved phase 129Xe is approxi-
mately 2% of that remaining in the alveolar spaces, which
presents a challenge to obtaining good quality images.[94a]
However, as the alveolar space, alveolar septa, and capillary
blood are in dynamic exchange, it is possible to use nearly all
of the inhaled gas to generate 3D images of dissolved 129Xe in
a single breath-hold, as demonstrated in a number of studie-
s.[94a,100]
Another challenge is to distinguish between xenon dissolved
in the alveolar septa and that dissolved in the blood. Various
teams have used the chemical shift and the change in reso-
nance frequency to distinguish xenon in these two compart-
ments[98a,101] as the dissolved-phase 129Xe signal splits into two
distinct peaks in alveolar septa and blood. These methods,
known as the Xenon Polarization Transfer Contrast
(XTC)[98a,101b,c] and the Model of Xenon Exchange (MOXE),[101a,d,e]
have been assessed in healthy volunteers[102] and patients with
obstructive lung disease,[102a] with promising results.
Further testing these methods, Kaushik et al.[94a] hypothe-
sized that there will be a reduction in 129Xe signal intensity in
the hemoglobin:alveolar septum ratio in patients with idio-
pathic pulmonary fibrosis (IPF), due to the thickening of the al-
veolar septa in this condition. MR spectroscopy was used to
demonstrate the change in relative signal intensity in patients
with IPF compared to healthy volunteers. The ratio was signifi-
cantly lower in the IPF group compared to the healthy volun-
teer group, due to a 52% reduction in the hemoglobin signal
and a 58% increase in the alveolar septa signal. There was
a strong correlation between the hemoglobin:alveolar septum
ratio and TLco. Therefore, this technique appears to provide
a non-invasive measure of diffusion limitation and gas-transfer
impairment.
These findings suggest that 129Xe-MRI has the potential to
detect subtle lung function deterioration before irreversible
structural changes become apparent, providing clinicians with
the chance to offer therapy (when available), at an earlier
stage in order to delay, halt or reverse disease progression.
3.8. Neuroimaging
129Xe-MR brain imaging is emerging as a distinct possibility.
Just as xenon can be used as a gas exchange probe due to its
ability to dissolve across the alveolar-capillary barrier, it can
also be used as a cerebral blood flow (CBF) probe, as it can
cross the blood–brain barrier and accumulate in the brain.[103]
First utilized in its non-polarized form for CBF measurement
using CT in 1982,[104] Swanson et al.[105] were the first group to
publish data on brain MR imaging using HP 129Xe as an inhaled
neuroimaging contrast agent, albeit in rats. Animal studies
have continued over the past two decades, using HP 129Xe as
both an inhalational[106] and injectable contrast agent.[107]
Diseased states have also been imaged in the rat model.
Xenon signal in the brain is proportional to CBF, hence a de-
crease in the signal is expected to occur in areas of decreased
CBF, such as those expected in ischemic stroke. Working on
this principle, Zhou et al.[108] created a rat model of cerebral is-
chemia by using an intraluminal suture to occlude the middle
cerebral artery, and demonstrated 129Xe-MRI is able to detect
the hypo-perfused area of focal cerebral ischemia, which was
also confirmed on biopsy. Mazzanti et al.[109] further demon-
strated the capacity of 129Xe-MRI for functional neuroimaging
by inducing pain in the rat’s forepaw, and obtaining 129Xe-MR
images, which showed 13–28% increase in signal compared to
the pre-stimulus images; these regions of increased signal cor-
responded to areas previously demonstrated by conventional
functional MRI (f-MRI) as being activated by a forepaw pain
stimulus.
It remains to be seen whether 129Xe-MR neuro-imaging is
feasible in humans and of value but developmental work is
on-going.
3.9. Conclusion
Biomarkers of disease can be classified into diagnostic, prog-
nostic, and theranostic. The ideal biomarker encompasses all
groups, and 129Xe-MRI has the potential to provide diagnostic,
prognostic, and theranostic biomarkers.
4. Brown-Fat MRI using Dissolved Hyperpolar-
ized 129Xe
For biological MR applications, one of the most interesting
properties of HP xenon is its high tissue solubility and its
chemical shift sensitivity to its molecular environment. Howev-
er, MR imaging and spectroscopy applications of dissolved-
phase HP xenon have been limited to brain and lung tissues
(as described in the sections above), as the concentration of
dissolved-phase xenon in other tissues is rarely high enough to
yield good signal after the typical single breath-hold protocol
used for human studies. Neglecting nuclear spin relaxation and
magnetization loss due to NMR pulsing, the time dependence
of xenon concentration in tissues Ci(t) is well described by the
Kety–Schmidt, Equation (3):[110]
C i tð Þ ¼ liCa 1@ e@
Fi
li
t
0 /
ð3Þ
where li, is the xenon partition coefficient between tissue and
blood, Ca is the arterial concentration of the inert gas, and Fi is
the blood flow to the tissue of interest. For most tissues, li,
which determines both the maximum concentration achieva-
ble in a given tissue and the time it takes to achieve maximum
concentration, is close to unity.[111] However, Fi, which also de-
termines wash-in rate, varies widely. For example, blood flow
to the brain is very high (~0.5 Lmin@1kg@1) and the maximum
xenon concentration in this tissue can be reached after a few
seconds from the beginning of gas inhalation. On the other
hand, while the solubility of xenon in fatty tissues is almost
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20 times higher than in blood, because of the low tissue-perfu-
sion (~0.01 Lmin@1kg@1), saturation can only be reached after
several minutes. For HP 129Xe gas, this is a clear limitation, as
gas depolarization would limit the amount of detectable signal
even under continuous HP xenon inhalation (because of short
in vivo T1 relaxation times).
It was recently shown that the intensity of the xenon dis-
solved-phase signal could reach much higher levels than in the
brain in a tissue called Brown Adipose Tissue (BAT).[112] Brown
adipose tissue is a fatty tissue found in most mammals, includ-
ing humans, and its primary function is to generate heat
through a process called non-shivering thermogenesis.[113]
During stimulation of non-shivering thermogenesis in this
tissue, intracellular triglyceride oxidation is decoupled from
ATP production so that triglycerides are mainly burned to pro-
duce heat. To support this metabolic activity, BAT is richly vas-
cularized. During non-shivering thermogenesis, tissue perfu-
sion increases by several fold as blood flow is needed to sup-
port the tissue’s oxygen demand and to quickly dissipate the
heat produced.
Aside from its thermoregulatory function, BAT has recently
gained a great deal of interest because of its presumed role in
the regulation of body weight and blood glucose level. For ex-
ample, a series of studies in rodents have clearly shown that
BAT function can directly regulate body weight and improve
insulin sensitivity.[114] However, the detection of this tissue still
remains a challenge, especially in humans,[115] where it is
sparsely distributed and not easy to detect by standard MR
techniques. In the paper by Branca et al. ,[23] a strong enhance-
ment of the intensity of the xenon-dissolved phase signal was
reported in mice inhaling HP 129Xe right after stimulation of
non-shivering thermogenic activity in BAT, an effect which was
ascribed to the strong enhancement in blood flow to BAT.[116]
Blood flow to this tissue during stimulation can reach values as
high as 5 Lmin@1kg@1,[116] considerably increasing xenon wash-
in rate and allowing it to reach an in-tissue concentration of
tens of mm. Since the increase in blood flow is specific to
brown fat cells, background free maps of this tissue could be
generated.
More interestingly, it was also shown that xenon chemical
shift information can provide a measure of the relative tissue
hydration and tissue temperature. Specifically, two major peaks
were observed in these studies. One signal, at ~197 ppm, cor-
responds to xenon dissolved in cell cytoplasm/blood, and one
signal at ~190 ppm corresponds to xenon dissolved in the
lipid droplets of the tissue. The lipid-dissolved peak was shown
to have a temperature-sensitive chemical shift (@0.2 ppm 8C@1),
which enabled direct measurement of the increase in tissue
temperature (Figure 5) during non-shivering thermogenesis.[23]
In addition, during non-shivering thermogenesis, a relative de-
crease of the lipid-dissolved phase peak was observed with re-
spect to the cytoplasm/blood peak, yielding direct evidence of
this tissue’s oxidative metabolism of internal triglycerides.
More recently, the feasibility of BAT detection in humans
during a single breath hold of HP xenon was demonstrated,
with validation by FDG-PET.[117] As in mice, a strong increase in
the lipid dissolved xenon signal was seen in the same glucose-
avid area of the supraclavicular fat depot. More interestingly,
xenon spectra showed, in addition to the lipid-dissolved phase
peak, a nearby peak around 200 ppm that was attributed to
xenon dissolved in red blood cells (RBCs), a signal that provid-
ed direct evidence of the strong increase in tissue blood flow
as the main drive for the increase in xenon tissue uptake.
By being a highly vascularized fatty tissue, BAT is clearly an
easy target for the lipophilic xenon. In this case, HP 129Xe gas
MRI is a “one-stop shop” for human BAT studies as it is capable
of providing both morphological and functional information.
5. 129Xe Cages and Hyper-CEST MRI
5.1. Bound xenon and molecular hosts
In addition to the NMR study of HP Xe in the gas phase and
the studies of tissue-dissolved Xe as described above, the affin-
ity of xenon to reside in hydrophobic pockets enables addi-
tional insights. This phenomenon made xenon a tool for ex-
ploring binding sites on protein surfaces[2c] with some effort
being put on spin polarization transfer to nuclei in nearby resi-
dues that form the catalytic site of enzymes. Hence, detection
of proton signals with and without adding HP nuclei could
identify the pocket-related residues.[111] Xe NMR spectra them-
selves can also show signals indicative of bound atoms. Such
a population could either cause a shift of the dissolution peak
or a distinct signal given the exchange rate would fall into the
right regime.[112] An example are red blood cells[113] where the
signal of “bound” Xe is ascribed to the interaction with hemo-
globin.[118] Several experiments first used lyophilized protein
powder samples, for example, of lipoxygenases.[119] NMR of dis-
solved Xe has been applied to identify binding pockets of lipid
transfer protein,[120] and for observation of conformational
changes in maltose binding protein,[121] and chemotaxis Y pro-
tein.[122] Besides specific site affinity for native structures, pro-
tein engineering also allowed for the design of conformation-
sensitive binding pockets as demonstrated with the ribose
binding protein.[123]
Figure 5. 129Xe brown adipose tissue (BAT) temperature map overlaid on
a sagittal 1H image. These temperature maps were obtained by using the
lipid-dissolved xenon signal as a temperature probe. The temperature coeffi-
cient of the lipid-dissolved xenon chemical shift was measured to be
@0.2 ppm 8C@1.
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The binding of Xe to synthetic hosts where the cavity has
a simpler design than in proteins can be even more pro-
nounced. a-cyclodextrin[124] still comes with fast exchange but
cucurbit[n]urils[125] (CBn, n=5, 6) show distinct peaks for
bound Xe, as do cryptophanes, a family of molecular cages
with some members that show rather high Xe affinity (K>
103m@1).[126] It has been shown that different members of this
group show distinct signals of bound xenon (Figure 6a). In par-
ticular cryptophane-A, CrA, is often used for conferring a dis-
tinct chemical shift to bound Xe ca. 130 ppm upfield from the
signal of free Xe in aqueous solution.
5.2. Xenon biosensor concept
These molecular cages triggered the field of Xe biosensors
where (for example) a variant of CrA is used as the NMR-active
reporter being tethered to a binding unit to reveal the pres-
ence of a certain analyte (Figure 6b). The first implementation
was shown with the biotin–avidin system.[127] This original pub-
lication also introduced the multiplexing option that this con-
cept offers. This feature is inherent to the different cage types
(like in Figure 6a), but also small chemical modifications on
the cage, for example, deuteration,[127b] already provide a host-
guest system with a different resonance frequency. Thus the
combination of different hosts with different targeting units
would allow for detecting multiple analytes simultaneously.
The sensing capability initially relied on a change in chemi-
cal shift and direct detection of the bound Xe signal-a concept
that was later partially revised due to anticipated loss of spec-
tral resolution in cells and live animals. Optimization for this
concept included first and foremost increasing the Xe affinity
and maximizing the detected chemical shifts. It is obvious that
the cage size impacts the binding constant as illustrated in
a comparative review,[128] but substitutions on CrA and crypto-
phane-111 can also increase the affinity.[129] Understanding the
details behind the complexation of Xe revealed induced fit
properties[130] and displacement of water[131] as contributing
forces. The linker length between cage and targeting unit is
a critical parameter for enabling the right balance between
sufficient mobility required for narrow resonances and desired
surface contact with the target to shift the signal.[132] Another
relevant aspect of cryptophane-based sensors is the poor
water solubility of the host. While many cages were first char-
acterized in organic solvents, various synthesis studies suc-
ceeded to improve solubility.[129c,131,133]
5.3. Hyper-CEST signal amplification
The focus on the binding properties somewhat shifted with
the advent of MR imaging protocols for such sensors. The low
concentration of caged atoms (typically <10@5m) requires ex-
tensive signal averaging for conventional detection. Initial
imaging applications were slow and limited to selected spatial
dimensions.[134] To improve this situation, the chemical ex-
change of Xe became an important parameter. One method
for enhanced sensitivity in spectroscopy applications uses se-
lective read-out of the caged Xe signal while the pool of dis-
solved Xe serves as a polarization reservoir.[135] This principle
was also used in imaging[136] but has its limitations due to the
timing that comes with frequency selective excitation pulses
with defined flip angles.
However, inverting the roles of the participating pools, that
is, manipulating the dilute pool and detecting the abundant
solution pool, enables significant signal enhancements. The
method with selectively saturating the magnetization from the
dilute pool (either through cw irradiation, or by using a train
of shaped excitation pulses) and observing the signal decrease
of the other pool (Figure 6c) is called chemical exchange satu-
ration transfer (CEST), first introduced by Balaban and co-work-
Figure 6. Caged Xe biosensor concept, and Hyper-CEST detection. a) Differ-
ent Xe hosts confer different chemical shifts to the bound atoms that
enable readout at distinct resonance frequencies. b) Xe inside a molecular
host changes its resonance frequency upon binding to a target structure.
c) Selective Hyper-CEST saturation at one of these frequencies causes
a cloud of depolarized Xe around the respective host. The reduced signal
from free Xe represents an amplified information from the small amount of
cages. d) Sweeping the saturation pulse over a certain frequency range and
subsequent observation of the magnetization from free Xe yields a Hyper-
CEST spectrum for comparing the performance of different hosts.
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ers.[137] Combining CEST with HP nuclei was first demonstrated
by the Pines lab for an imaging application and coined Hyper-
CEST.[138] With Hyper-CEST, host concentrations as low as
~10@8m become accessible-even for imaging.[139] The effect
strongly depends on the exchange rate and therefore it can
also sense system parameters like ambient temperature.[140]
The spectral dimension can be recovered by performing
a series of experiments in which the saturation pulse is swept
over a certain frequency range (Figure 6d), thus providing an-
other method to sense parameters that influence the chemical
shift.[141] It also preserves the multiplexing option mentioned
early on.
5.4. Xe Biosensor Applications in Cell Biology
The improved detection limits for imaging made it possible to
address problems under more biologically realistic conditions.
To date, cryptophane-based sensors that use specific binding
to the target have been implemented for sensing the enzyme
MMP7,[142] nucleotides,[143] human carbonic anhydrase,[144] MHC
class II,[145] zinc ions,[146] the glycoprotein CD14[147] and the re-
ceptors for integrin,[148] transferrin,[149] EGF,[150] and folate.[151] An
indirect binding approach was pursued through in situ click
chemistry with metabolically labeled cell surface glycans.[152]
Conformational changes of the sensor induced by changes in
pH represent an approach for stimulus-induced binding.[153]
As part of these studies, cell uptake and toxicity evaluations
set the bar for target concentrations of functionalized
hosts.[148,154] Xe itself passes the cell membrane[149] and does
not require further attention to reach intracellular targets. Cell-
penetrating peptides proved to be a valuable measure for ach-
ieving micromolar intracellular concentrations. However, they
are not an absolute requirement since the hydrophobic charac-
ter of CrA can mediate membrane association and therefore
enables certain types of cellular labeling.[155] Sensors with
highly specific binding motifs (e.g. , antibodies[147, 150] or bioor-
thogonal reaction partners)[152] only require sample-averaged
concentrations of 10@8m for MRI.
Critically, the membrane affinity of CrA can be clearly identi-
fied by a ca. 10 ppm downfield shift for Xe in membrane-asso-
ciated CrA.[156] This property proved primarily useful to identify
cell-associated cages in the first live-cell experiments.[149, 155a] A
closer look in combination with FRET data revealed partition-
ing coefficients on the order 102–103 for different membrane
compositions.[157] This work also initiated a new class of Hyper-
CEST experiments for investigating membrane fluidity and in-
tegrity : Due to the accelerated exchange, Xe signals from
membrane-embedded cages do only differ marginally in chem-
ical shift. However, build-up of the CEST effect can be very dif-
ferent depending on membrane fluidity. Comparative studies
are possible when irradiating a pool of caged Xe at fixed satu-
ration power and frequency but increasing saturation time.
Evaluating the (multi-)exponential depolarization with an in-
verse Laplace transformation yields characteristic time con-
stants for different environments.[158] The method called DeLTA
(depolarization Laplace transform analysis) can also be used to
discriminate cholesterol content and the onset of lipid domain
fluctuations.[159]
5.5. Host Optimization
In order to explore a large chemical shift range of different
sensors, the impact of metal ion chelation in close proximity to
the cage provides a means to diversify signals.[160] Along this
line, attached Gd-chelates can serve as relaxation switches for
129Xe which are detachable through chemical reactions.[161] Re-
garding Hyper-CEST detection, improved efficiency depends
on the exchange properties, which are sub-optimal for CrA.
Faster exchanging hosts such as CB6[162] and CB7[163] are cur-
rently under investigation. Their binding properties for com-
petitive guests must be taken into account but this versatile
binding phenomenon on the other hand enables the option to
implement detection of other guests via displacements ap-
proaches. An example is the mapping of lysine decarboxylase
(LDC) activity where the enzymatic product cadaverine
quenches the Hyper-CEST effect.[163] Related to this is an imple-
mentation of a sensor relay in which the cavity becomes acces-
sible for Xe as soon as another host recruits the original guest
from the CB6 cavity.[164] The macrocyclic host also allows con-
struction of rotaxanes that keep the cavity blocked. Cleaving
one of the rotaxane stoppers releases the thread and makes
CB6 available for Hyper-CEST detection.[165] This recent design
could serve as a development platform for various sensors
based on cleavage reactions.
Many dilute targets will only be accessible with an increased
number of CEST sites per targeting unit. For this purpose, mul-
tivalent carriers with 102@103 Xe hosts will be the right tool.
They have been implemented with scaffolds such as bacterial
phages,[150,166] viral capsids,[167] and liposomes.[168] Alternatively,
nano-compartments absorbing small amounts of Xe gas can
be used, one example being PFOB nanodroplets.[169] The first
imaging experiments with the latter substance also included
the first multi-channel read-out of different host classes.[155b]
Similar host compartments such as gas vesicles[170] and bacteri-
al spores[171] will be discussed separately in the following sec-
tion.
5.6. Hyper CEST Analysis and Data Encoding
Stable and reproducible HP Xe delivery with shot-to-shot noise
<1% achieved through temperature stabilization of the
pumping cell[172] allows one to further investigate the predict-
ed line-shape for Hyper-CEST spectra, that is, an Lorentzian.[173]
Linked to this theoretical description is an approximation for
the Bloch–McConnell equations that allows prediction of the
build-up of the Hyper-CEST effect and quantification of the ex-
change parameters.[174] Comparison of hosts can then be done
by using the gas turnover rate.[162b] The exchange dynamics
also set the boundary conditions for maximum signal contrast
and an orientation for optimum saturation parameters.[175] It is
important to achieve the saturation transfer before the intrinsic
T1 relaxation dominates with its signal loss.
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For imaging, the CEST information needs to be encoded as
fast as possible. Fast imaging sequences can replace the origi-
nal point-wise encoding[138] given that sufficient magnetization
is available. Echo planar imaging (EPI) allows sub-second imag-
ing,[139] with particular application to hyperpolarized imaging
using variable flip-angle excitation in an approach called
smashCEST. These rapid imaging approaches enable time-re-
solved studies, including the monitoring of diffusion.[139] Image
quality can be improved by exploiting redundancies in the
spectral domain[176] during encoding and post-processing.
Spin-echo encoding is an alternative for cases where T2* relaxa-
tion makes EPI encoding impractical.[155a] Interest in Hyper-
CEST agents has led to the development of fast strategies for
gradient-encoded CEST spectra at up to 40-fold reduced scan
times.[177]
6. Genetically Encodable Hyperpolarized 129Xe
MRI Contrast Agents
Genetically encoded MRI reporters are contrast agents that can
be produced by genetically transfected cells to enable the
tracking of cells, imaging of gene expression, or sensing of
specific aspects of cellular function. Among the advantages of
these reporters over synthetic agents are that they can be in-
troduced into cells using established gene-delivery techniques,
avoid dilution with cell division, and that a large genetic engi-
neering toolbox can be used to modify and optimize protein-
based reporter performance. Furthermore, these agents lever-
age the recent boom in molecular biology methods to manip-
ulate and deliver genetic materials to animals, such as trans-
genic mouse lines, viral therapy, RNA interference, and
genome editing.
Most existing genetic reporters have been designed for 1H
MRI. Examples include enzymes or transporters that can act on
synthetic contrast agents,[178] proteins that naturally contain
paramagnetic metals, including ferritin,[179] MagA,[180] MntR,[181]
tyrosinase,[182] and cytochrome P450,[183] and diamagnetic CEST
agents such as lysine rich-protein,[184] human protamine sul-
fate[185] and proteins that alter water diffusivity in tissue.[186]
Comparatively fewer contrast agents have been designed for
heteronuclear MRI, all of them based on enzymatic or trans-
porter interactions with 19F compounds,[187] HP 13C com-
pounds,[187c,188] or 31P substrates.[189] A major challenge of all of
these agents is their relatively low molecular sensitivity, typical-
ly of the micromolar or higher order, which limits their range
of in vivo applications. Several excellent reviews have been
written on these classes of MRI reporters.[190]
Given the sensitivity gains of HP 129Xe MRI and in particular
HyperCEST, there is a strong incentive to develop genetically
encoded MRI reporters acting on xenon. However, this pros-
pect is challenging due to the weak interaction of xenon with
most proteins. Xenon-binding proteins have been identified
through X-ray crystallography, wherein xenon is used as
a heavy atom marker to aide in structure elucidation,[191] and
NMR, wherein the 129Xe chemical shift can probe proteins’ con-
firmation and ligand binding.[192] Examples of proteins shown
to interact with xenon include myoglobin[193] and hemoglobin,
maltose-binding protein[112] and lysozyme.[119] These interac-
tions are attributed primarily to enthalpic Debye and London
interactions, with a smaller entropic contribution from xenon
dehydration as it enters a hydrophobic cavity.[192b] Unfortunate-
ly, although protein binding was shown to shift the resonance
frequency of xenon by several ppmmm@1, these proteins are
not suitable as 129Xe-MRI contrast agents because their xenon
affinities (~10 mm) would require unrealistic quantities of pro-
tein to be present to achieve significant direct contrast, while
their xenon exchange rates (dissociation constant ~105 s@1)[193]
are too fast compared to the induced xenon chemical shift
(Dw~103@104 s@1) to enable efficient HyperCEST contrast.
A major advance in the development of genetically encoded
reporters for Xe-MRI was made in 2014, when Shapiro et al. re-
ported that an unusual class of gas-filled protein nanostruc-
tures called gas vesicles (GVs) could produce efficient HyperC-
EST contrast at picomolar concentrations.[25] GVs, which
evolved in photosynthetic microbes as a means to regulate
buoyancy, comprise hollow gas compartments at hundreds of
nm in size and possess a 2 nm protein shell that is permeable
to gas but excludes liquid water[194] (Figure 7a,b). Shapiro et al.
showed that GVs can interact with xenon to produce HyperC-
EST contrast with peak saturation approximately 175 ppm up-
field from dissolved 129Xe (Figure 7c,d). The large chemical shift
separation enables the contrast to be extremely efficient, with
Figure 7. Gas vesicles as genetically encodable HyperCEST reporters detecta-
ble at pM concentrations. (a) Diagram of a gas vesicle : a hollow gas nano-
compartment (solid shading) surrounded by a gas-permeable protein shell
(ribbed shading). (b) Transmission electron micrographs of individual GVs
purified from Halobacterium NRC-1 in their intact (left) and collapsed (right)
state. (c) Diagram of 129Xe CEST between bulk aqueous solvent (left) and GVs
(hexagons) either in isolation or inside a cell (gray). (d) Frequency-dependent
saturation spectra for intact (red) and collapsed (black) GVs. (e) Saturation
contrast image of a three-compartment phantom containing 400 pm GVs,
100 pm GVs and buffer. Reprinted by permission from Macmillan Publishers
Ltd: Nature Chemistry,[170] copyright 2014.
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a GV detection limit in the picomolar range (Figure 7e), orders
of magnitude lower than comparable proton contrast agents.
Furthermore, GVs formed by different species of bacteria and
archaea, in which these nanostructrues differ in size and shape,
produce HyeprCEST saturation at different chemical shifts,
thereby enabling multiplexed imaging. In their initial study,
Shapiro et al. provided proofs of concept for GVs as antibody-
functionalized markers of cancer cells and as reporters of gene
expression in E. coli. In addition to GVs, other biological struc-
tures may be able to serve as HyperCEST agents. For example,
bacterial spores, a dormant cellular state comprising a multi-
layered structure of ~1.5 mm size, were recently demonstrated
for HyperCEST at a chemical shift 4.5 ppm downfield from
aqueous xenon.[171]
The discovery of GVs as highly efficient biomolecular report-
ers for HyperCEST leads to several interesting questions and
possibilities that merit further investigation. If we assume that
an optimal CEST saturation can always be achieved with suffi-
cient RF power and that the relaxation of 129Xe is minimal
during CEST experiment, then HyperCEST sensitivity is deter-
mined by (a) the chemical shift difference and (b) the exchange
rate between the contrast-agent-bound and the dissolved
129Xe spins.[195] Regarding the chemical shift, each GV has a sev-
eral-attoliter gas chamber containing thousands of gas atoms
or molecules, where 129Xe atoms presumably experience an en-
vironment similar to gas phase, and consequently compared
to the synthetic contrast agents, GV-associated 129Xe chemical
shift is usually closer to that of the gas phase. Intriguingly, the
specific value of chemical shift appears to be genetically deter-
mined.[25] It will be interesting to study how this chemical shift
relates to other genetically encoded GV properties, including
their size, shape and aggregation state, and the extent to
which these properties can be tuned at the genetic level. In
terms of the exchange rate, when the Z spectra (i.e. , the fre-
quency-dependent saturation effects are visualized similar to
conventional magnetization transfer spectra by plotting the
water saturation (Ssat) normalized by the signal without satura-
tion (S0) as a function of saturation frequency) acquired with
intact and collapsed GV are compared with those acquired
with synthetic agents, both the GV-bound and the dissolved
129Xe peaks appear to be broader, suggesting the exchange
rate is in the intermediate regime. It will be interesting to
define quantitatively the optimal RF saturation parameters for
the specific exchange rate of GVs. On the molecular level,
though the atomic-level structure of the GV wall has not been
solved, some hypotheses have been proposed regarding the
channels on the protein shell that allow gas exchange in and
out of the nanostructure;[194b] it is possible that variation (natu-
ral or engineered) in the amino acid sequence of GV proteins
could alter the permeability of these putative pores. Taken to-
gether, GVs present a wide dynamic range for 129Xe chemical
shifts and exchange rates, and these two properties are likely
amenable to protein engineering for new and optimized forms
of 129Xe HyperCEST.
It is also worth noting that in addition to serving as HyperC-
EST reporters, GVs produce contrast in at least two comple-
mentary imaging modalities. First, they are the first genetically
encodable imaging agents for ultrasound,[196] where their low
density and high elasticity relative to surrounding media
allows them to scatter sound waves. Secondly, their gas-filled
interior, which has a different magnetic susceptibility from sur-
rounding solution, allows GVs to produce 1H MRI contrast in
susceptibility-weighted imaging.[197]
The list of genetically encoded 129Xe-based HyperCEST re-
porters has been recently expanded to include b-lactamase by
Dmochowski and co-workers.[198] As a small protein encoded
by a single gene, this reporter may be easier to use in some
settings than GVs, albeit with somewhat lower molecular sensi-
tivity.
7. Parahydrogen
Hydrogen exists in two nuclear spin isomers, denoted as ortho-
and para-, corresponding to the nuclear triplet and singlet
states, respectively: here parahydrogen corresponds to the
states with an even rotational quantum number J whereas or-
thohydrogen corresponds to odd values of J. The ratio of the
two isomers is determined by the Boltzmann thermal equilibri-
um for the given temperature, Figure 8.[199] For a more detailed
discussion of the physics and applications of parahydrogen
beyond the scope of this Minireview, we refer the interested
reader to the 1935 book by Farkas on hydrogen[199] or various
excellent discussions.[200]
Importantly, conversion between the two states occurs ex-
tremely slowly due to the transition being forbidden by the se-
lection rules of quantum mechanics, leaving only statistically
unlikely naturally occurring processes of sufficient energy (radi-
ation, molecular collisions, etc.) to foment interconversion.
Therefore, after its production (and provided lack of exposure
to sources of paramagnetic impurities in the storage vessel),
parahydrogen may be stored for long periods before use, as
the relaxation rate of the parahydrogen back to room-temper-
ature equilibrium can be on the order of months.[201] Produc-
tion rates are significantly faster, however, since as discovered
in 1929 by Bonhoeffer and Harteck, the use of paramagnetic
catalysts (i.e. , activated charcoal, nickel, hydrated iron(III)
oxide) promotes establishment of Boltzmann thermodynamic
equilibrium between ortho-H2/para-H2 states for a given tem-
perature at greatly accelerated rates. In practice, normal hydro-
gen gas (i.e. , equilibrium ratio at room temperature) consisting
of 75% ortho- and 25% para- isomers is passed through cham-
ber filled with paramagnetic catalyst and maintained at cryo-
genic temperatures, where the equilibration to the isomer
ratio governed by the Boltzmann distribution occurs. For ex-
ample, a parahydrogen generator operating at 77 K (obtained
conveniently by a liquid-N2 bath) yields a mixture with ~50%
parahydrogen, whereas the designs based on cryo-chillers (e.g.
T ,20 K) yield +99% parahydrogen (Figure 8).
8. Fundamentals of Parahydrogen-Induced
Polarization (PHIP)
In 1986 Bowers and Weitekamp proposed a method for achiev-
ing very high nuclear polarizations using parahydrogen.[7a]
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Dubbed PASADENA (Parahydrogen And Synthesis Allow Dra-
matically Enhanced Nuclear Alignment), the effect predicted
strongly enhanced 1H NMR signals for hydrogenation reaction
products when unsaturated molecular precursors are hydro-
genated with parahydrogen. Later they demonstrated the
effect experimentally by hydrogenating acrylonitrile with para-
hydrogen using Wilkinson’s catalyst.[7b] Anti-phase 1H NMR mul-
tiplets were demonstrated for the reaction product, propioni-
trile, and for dihydride rhodium complex—the reaction inter-
mediate. It was later realized that experimental demonstrations
of the PASADENA effect had already been published,[202] but
had been misinterpreted as chemically induced dynamic nucle-
ar polarization.[7c] PASADENA and (the later discovered) ALTA-
DENA[203] are collectively referred to as parahydrogen-induced
polarization (PHIP).[11c] This seminal discovery of Bowers and
Weitekamp opened up a new strategy for hyperpolarization of
various compounds, and currently PHIP and its recent modifi-
cation, SABRE (Signal Amplification By Reversible Exchange),[8]
are used to obtain HP molecules with 1H,[11c,200b] 13C,[12] 15N,[13d]
19F,[14] and 31P[15] nuclei in a hyperpolarized state.
Detailed explanation of the spin dynamics and chemical ki-
netics behind PHIP can be found in several comprehensive re-
views.[11c,200,204] Here we briefly discuss the main principles of
PHIP to qualitatively describe the phenomena discussed below.
As an example, we take the simplest two-spin system. The
two-spin system of the hydrogen molecule gives rise to four
nuclear spin energy levels. As described above, three of these
energy levels correspond to orthohydrogen, the state with
total nuclear spin 1 (triplet state), whereas the remaining
fourth energy level corresponds to parahydrogen (singlet
state), the state with zero total nuclear spin. Transitions be-
tween singlet and triplet spin states are forbidden by symme-
try;[7a] and the spin 0 parahydrogen is NMR-silent.
Bowers and Weitekamp’s idea was to break the magnetic
equivalence of two hydrogen nuclei by using parahydrogen in
a hydrogenation reaction (Figure 9a), thus, making prohibited
transitions allowed. Indeed, upon incorporation of a parahydro-
gen molecule into an asymmetric molecular precursor, the
symmetry of the para-H2 molecule becomes broken. This situa-
tion strongly depends on the magnetic field at which the hy-
drogenation reaction takes place. If hydrogenation is per-
formed at high magnetic field B0 (i.e. , wherein the chemical
shift difference between the two para-H2-nascent protons, Dd,
is much greater than the spin-spin coupling J between them
(gDdB0 > 2pJ)), then the population of the singlet spin state
(ab@ ba) of para-H2 is transferred to the population of spin
states ab and ba of the formed weakly coupled AX spin
system (PASADENA effect, Figure 9b).[7b] The NMR spectrum of
the AX system populated in this way will contain four peaks
grouped in two antiphase multiplets (Figure 9b).
Two lines (positive-negative or negative-positive, depending
on the sign of spin–spin coupling constant J) in each multiplet
are separated by J Hz in the case of isotropic liquids and/or
gases.[205] The PASADENA-hyperpolarized organic molecules are
typically manifested in 1H NMR spectra as positive-negative
multiplets, whereas multiplets for hydride intermediates are
negative-positive, since J couplings are usually negative for
metal hydrides.[206] Interestingly, the signal intensity of PASADE-
NA spectrum is maximized when a 458 (instead of 908) pulse is
applied for signal acquisition, which may be shown using
a density operator description of the PHIP process.[204]
On the other hand, if the hydrogenation reaction takes
place at low magnetic field (such that gDdB0 , 2pJ ; e.g. , at
the Earth’s magnetic field), and afterwards the hydrogenation
Figure 8. Parahydrogen conversion. Passage of H2 gas over a paramagnetic
catalyst, given sufficient contact time, converts the ortho-H2 fraction to para-
H2 fraction as a function of temperature.
Figure 9. a) Molecular diagram of parahydrogen (para-H2) addition to the
substrate performed with a homogeneous or heterogeneous catalyst. b) PA-
SADENA effect: nuclear spin energy level diagram of para-H2 at high mag-
netic field (left). An AX spin system is formed upon pairwise addition of
para-H2 to the unsaturated substrate at high magnetic field and correspond-
ing 1H NMR spectrum is shown on the right. c) ALTADENA effect: nuclear
spin energy level diagram of para-H2 at low magnetic field (left). An AB spin
system is formed after pairwise para-H2 addition to the unsaturated sub-
strate at low magnetic field. An AX spin system is obtained after adiabatic
transfer of the reaction product from low to high magnetic field. The corre-
sponding 1H NMR spectrum is shown on the right.
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product is adiabatically transferred to a high magnetic field,
then there is a single state that is overpopulated, that is, ab or
ba-depending on the sign of the J-coupling constant between
the nuclei (ALTADENA effect, Figure 9c).[203] In this case after
a 908 pulse the spectral pattern will consist of four lines group-
ed in two “integral multiplets” simply corresponding to one
spin “up” and second spin “down” state (Figure 9c).
In order to be able to observe PHIP for the molecule of in-
terest several key conditions must be fulfilled:[11c]
1. The addition of parahydrogen to the unsaturated precursor
should occur in a pairwise manner. Pairwise addition im-
plies that two hydrogen atoms from the same H2 molecule
are included in the product molecule together as a pair,
thus preserving spin correlation between the two proton
spins.
2. The characteristic nuclear spin relaxation time for para-H2-
nascent protons should be longer than the time needed to
complete the pairwise hydrogenation process.
3. The magnetic equivalence of the two correlated nuclear
spins should be broken during the hydrogenation[207] or in
the product of the hydrogenation reaction.[7b]
If all of the above-mentioned conditions are fulfilled, the
product of the hydrogenation reaction will possess a non-equi-
librium population distribution of its nuclear spin energy levels
owing to either the PASADENA or ALTADENA process.
One should note that the final polarization of the hydroge-
nation reaction product does not depend on the magnetic
field strength, and the polarization obtained by PHIP in princi-
ple can reach 100% (neglecting spin relaxation and/or deco-
herence).[7a,204] In principle, enhancement of the NMR signal
can be as high as several thousand-fold above ordinary ther-
mal signals from high-field NMR spectrometers and even a mil-
lion-fold at low magnetic fields.
Since the hydrogenation reactions have a significant activa-
tion energy barrier, the key component of the system is a cata-
lyst (Figure 9a), which (i) enables the hydrogenation reaction,
and (ii) provides efficient pairwise addition of molecular hydro-
gen to the substrate. All hydrogenation catalysts can be classi-
fied as homogeneous or heterogeneous depending on their
phase relative to the substrate. Homogeneous catalysts are
present in the same phase as the to-be-hydrogenated sub-
strate (typically, liquid phase), whereas heterogeneous catalysts
are present in a phase different from the phase of the sub-
strate (usually, a solid catalyst and a gaseous or liquid sub-
strate). Since the first demonstration by Bowers and Weite-
kamp,[7b] homogeneous catalysts have become widely used to
produce PHIP, which is reasonable: it is known that hydrogena-
tion mechanisms using metal complexes can usually provide
an efficient route for pairwise hydrogen addition. For a long
time, the feasibility of using heterogeneous catalysts for pro-
duction of PHIP was rejected based on the known mechanism
of heterogeneous hydrogenation, that is, the Horiuti-Polanyi
mechanism. According to Horiuti and Polanyi,[208] hydrogen
molecules dissociate on metals (typically used as heterogene-
ous hydrogenation catalysts) and form a pool of randomly
moving free hydrogen atoms, thus ostensibly not fulfilling con-
dition 1 (pairwise addition) above.[209] Nevertheless, it was
shown that various classes of heterogeneous catalysts, that is,
immobilized metal complexes,[9a] supported metal nanoparti-
cles,[28b] etc. , can enable the PHIP effect. In the current mini-
review both classes of catalysts are considered.
9. Gases Hyperpolarized via PHIP
As mentioned in the introduction, MRI of gases suffers from
poor sensitivity due to their low molecular density combined
with the low thermal polarization of their nuclear spins. These
problems can make it challenging to image gas-filled void
spaces due to the very low signal-to-noise ratio (SNR) and the
usually long signal-averaging times, which can be prohibitive
for many clinical applications. HP noble gases[210] can be used
to address these issues. However, the production of HP noble
gases is relatively expensive, necessitating costly hyperpolarizer
equipment. Moreover, imaging of HP noble gases requires
a dedicated X-band channel (for the heteronucleus of interest)
and radio-frequency probe, which are not standard features of
clinical MRI scanners (although they are becoming increasingly
prevalent). Therefore, production of non-toxic HP proton-con-
taining gases via PHIP could be a promising alternative that
avoids the above technical requirements of HP noble gases.
9.1. Production of Hyperpolarized Gases Using PHIP
Historically, experiments with parahydrogen were predomi-
nantly conducted in the liquid phase, wherein fluids hyperpo-
larized by PHIP reside in a solution along with a homogeneous
hydrogenation catalyst.[200b] Heterogeneous catalysts can be
used to separate the HP product from the catalyst.[29,211] At the
same time, it is also possible to produce catalyst-free HP gases
by combining the main advantage of homogeneous (high se-
lectivity) and heterogeneous catalysis (easiest catalyst separa-
tion) by using gas-liquid biphasic hydrogenation. Utilization of
a homogeneous catalyst dissolved in the liquid phase for bi-
phasic hydrogenation of unsaturated gases with para-H2
allows one to produce HP gas that is free from contamination
by the catalyst. In the demonstration of this approach it was
shown that the reaction product can return to the gas phase
while retaining a significant degree of hyperpolarization.[212]
This feature significantly extends the range of gases that
can be hyperpolarized. It was shown that utilization of
a simple experimental procedure allows one to achieve signal
enhancements of 300 for propyne hydrogenation to propylene
using the bidentate cationic complex [Rh(PPh2-(CH2)4-
PPh2)(COD)]BF4.
[212] Another approach for HP gas production is
the use of homogeneous catalysts based on a careful choice of
the metal complex (homogeneous hydrogenation catalyst) in
which the desired unsaturated substrate is coordinated to the
metal center.[213] In that case hydrogenation of the substrate
with parahydrogen allows the product to leave the metal
center and to migrate to a different phase with preservation of
the spin order of the two nascent protons derived from the
para-H2 molecule. Indeed, it was shown that PHIP-hyperpolar-
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ized gas can be obtained in a catalysis-free regime using
a chemical reaction with molecular addition of parahydrogen
to a water-soluble Rh(I) complex carrying a payload of a com-
pound with double (C=C) bonds.[213] Hydrogenation of the nor-
bornadiene ligand leads to the formation of norbornene,
which is expelled from the RhI complex to the aqueous phase,
but due to its insolubility in water HP norbornene migrates
from the solution to the gas phase (Figure 10).[213]
As soon as PHIP was successfully demonstrated in heteroge-
neous hydrogenations over immobilized[9a] and supported
metal catalysts,[28b] the production of HP gases over these cata-
lysts became an important area of PHIP-related investigations.
Many different heterogeneous catalysts were used for the pro-
duction of HP gases in the past eight years, with the aim to
find the catalyst with the highest level of pairwise hydrogen
addition for a given substrate.[29,214] Without doubt the utiliza-
tion of a solid catalyst allows one to produce HP gases in the
continuous-flow regime by passing a mixture of an unsaturat-
ed substrate with para-H2 through the catalyst layer. In this ap-
proach, hydrogenation occurs at the Earth’s magnetic field and
corresponds to the ALTADENA[203] type of PHIP experiment.
Note that the nature of the heterogeneous solid catalyst can
have a significant impact on the polarization level, and titania-
supported metal catalysts were shown to exhibit larger PHIP
effects compared to metals on other supports.[215] The polariza-
tion level for HP gases produced over supported metal cata-
lysts can be several percent,[28b,216] and it can change with the
variation of the size of the supported metal nanoparticles.[217]
Larger polarizations are observed for smaller Pt particles, but
for Pd there is an opposite trend.
9.2. MRI of Hyperpolarized Hydrocarbon Gases
Continuous production of HP gases via heterogeneous hydro-
genation paves the way to the potential practical applications
for imaging of void spaces by MRI. The first experiments were
related to MRI visualization of HP propane in a NMR tube with
a cross-shaped partition or with a series of capillaries.[9b] For
that work, a mixture of para-H2 and propene gas was flowed
through a reactor cell with the heterogeneous catalyst (e.g. ,
Wilkinson’s catalyst immobilized on silica). After that the prod-
uct (HP propane gas) was transferred to the NMR magnet and
the ALTADENA enhancement was evident in the MR images.
For both model samples, detection of the NMR signal of
a thermally polarized gas did not produced observable images,
whereas the use of PHIP-polarized propane gas allowed one to
visualize the corresponding structures of the objects used in
the experiments.[9b] Importantly, the demonstrated 300-fold
signal enhancement in the gas-phase MRI is sufficient to image
gases with a similar spatial resolution as that in corresponding
liquid-phase MRI experiments. The subsequent development
of the strategies for 1H MRI visualization of both hyperpolar-
ized (Figures 11 and 12) and thermally polarized propane gas
for high-resolution MRI applications allowed one to significant-
ly decrease the imaging time. Compared to FLASH MRI[218]
(Figure 12), the use of UTE MRI[219] decreases the total imaging
time significantly, down to the regime sufficient for MRI of a pa-
tient within a single breath-hold in a future clinical translation.
It was shown that utilization of UTE MRI makes it possible to
obtain 2D images of thermally polarized propane gas with ca.
0.9V0.9 mm2 spatial resolution in ca. 2 s (and potentially with
better resolution for HP gases).[220]
Recently, HP propane gas produced by heterogeneous hy-
drogenation of propene over supported metal catalysts was
utilized for 3D 1H MRI with micro-scale spatial resolution (625V
625V625 mm3), large imaging matrix size (128V128V32) and
short (17.4 s) image acquisition time.[215a]
Utilization of a fully deuterated substrate (propene-d6) in the
heterogeneous hydrogenation with para-H2 permitted acquisi-
tion of a high-resolution 3D MRI image of flowing HP [D6]-pro-
pane gas with 0.5V0.5V0.5 mm3 spatial and ~18 s temporal
resolution (Figure 13a).[221] It was shown that the signal-to-
noise ratio in the 3D images of HP [D6]-propane gas (Fig-
Figure 11. Heterogeneous pairwise hydrogenation of propene to propane
with para-H2 over Rh/TiO2 catalyst with preservation of spin order of parahy-
drogen in the final HP product.
Figure 10. ALTADENA 1H NMR spectra of a gaseous stream during bubbling
of parahydrogen (a) and normal H2 (b) through the solution of
[Rh(I)(NBD)L]+BF4
@ in D2O at 70–80 8C. The broad signal labeled “H2” belongs
to ortho-H2 gas: the resonances labeled with open circles correspond to nor-
bornane. c) Diagram of the experimental setup with the NMR detection per-
formed in the high field. Reprinted with permission from ref. [213], Copy-
right (2014) American Chemical Society.
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ure 13a) and water (Figure 13b) are similar. This observation
confirms that the utilization of a gas hyperpolarized by PHIP
allows one to obtain MR images with quality similar to that ob-
tained with water as the signal source.
Utilization of HP gases produced by PHIP is not limited only
to void space imaging. Indeed, it was shown that a catalytic re-
actor positioned inside an NMR magnet can be imaged in situ
during heterogeneous hydrogenation of propene to propane
with parahydrogen.[28a] In situ MRI of a catalytic reaction allows
one to visualize the regions in the catalyst layer where the hy-
drogenation reaction occurs. Importantly, based on the signifi-
cant signal enhancement the velocity map for HP gas forming
in and flowing through the catalyst bed was obtained.[28a]
Given the above results, PHIP is clearly becoming an impor-
tant technique for signal enhancement in both basic science
and biomedical MRI investigations. Moreover, the use of PHIP
to produce HP gases can be useful for their potential utiliza-
tion in medical MRI applications.
10. Remote-Detection MRI of Hyperpolarized
Gases
MRI of gases in small voids, such as in porous media, micro-
reactors, and microfluidic devices, suffers from particularly low
sensitivity due to an additional exacerbating factor : low filling
factor of the NMR coil, which may be less than 10@5 in some
cases. While HP methods partially compensate for the low sen-
sitivity, an additional sensitivity boost provided by alternative
detection methods may be required. These methods include,
for example, surface RF microcoils, RF microslots, and remote
detection (RD), to name a few.[222]
In RD MRI,[223] encoding of spatial information and signal de-
tection are performed with different coils in different locations
(see Figure 14a). The encoding RF coil is a large coil around
the whole sample, so that all spins can be excited. Signal de-
tection is performed outside the sample with a much smaller
and more sensitive RF coil, with an optimized filling factor.[224]
The technique requires that the encoded spins are transported
to the detector before the magnetization is fully relaxed, and it
inflicts one additional dimension as compared to conventional
MRI, because it is based on phase encoding only. Nevertheless,
it provides a substantial sensitivity boost as an ultrasensitive
detection solenoid may be hundreds of times more sensitive
than the encoding coil.[225] Furthermore, the flow delivers spins
Figure 14. RD MRI of flow of HP 129Xe through a rock sample. a) The rock sample is inside a large RF coil used to encode spatial information into spin coher-
ences, and the signal is read out by a smaller and more sensitive coil around the outlet tubing, with optimized filling factor. b) 3D TOF images. The silhouettes
represent the rock sample. TOF, i.e. , the time instant the signal is detected after the encoding, is shown above the images. Reprinted with permission from J.
Granwehr, E. Harel, S. Han, S. Garcia, A. Pines, P. N. Sen, Y. Q. Song, Phys. Rev. Lett. 2005, 95, 075503. Copyright (2005) by the American Physical Society.
Figure 12. (a) Schematic representation of the experimental setup for using
PHIP to produce HP propane via heterogeneous hydrogenation of propene
with parahydrogen. (b) 1H MRI FLASH image of HP propane flowing into
a 10 mm NMR tube via 1/16 in. OD Teflon capillary. Note that the NMR tube
is shown schematically and its length does not match the actual scale of the
2D MR image. Reprinted with permission from ref. [220].
Figure 13. High-resolution 3D gradient echo (GRE) MRI at 4.7 T. a) 3D MRI of
flowing HP propane gas (~20 mm concentration) with 0.5V0.5V0.5 mm3
spatial and 17.7 s temporal resolution and 32V32V32 mm3 field of view.
b) The corresponding image of (stationary) thermally polarized tap water
(55m). Reprinted with permission from ref. [221], Copyright (2014) American
Chemical Society.
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from the different parts of the sample to the detector at differ-
ent times, and this inherent time dimension can be utilized to
produce time-of-flight (TOF) flow images.[226]
10.1. Time-of-Flight Flow Imaging with HP Gases
HP Xe is an ideal probe fluid in RD MRI experiments, because
the T1 relaxation time of
129Xe can be extremely long, allowing
correspondingly long transport times from the sample to the
detector. HP Xe RD MRI has been used for imaging flow
through porous materials,[223, 227] rocks,[226] microfluidic devi-
ces,[225] and wood,[228] as well as for quantifying diffusion
through membranes.[229] Figure 14b shows a remarkable exam-
ple of 3D TOF images of HP Xe flowing through a rock sample.
The shortest TOF image (TOF=0.27 s) shows spins that were
at the top of the encoding region, because they arrived first to
the detector, and the longest TOF image (TOF=0.98 s) shows
the spins at the sample bottom.
Gaseous HP hydrocarbons produced by PHIP have been
used in RD MRI experiments as well.[230] T1 values for spins of
hydrocarbons are typically much shorter (~1 s) than that of
129Xe, limiting the transport time of fluid from the sample to
the detector ; however, if the sample coil and the detection coil
are close enough and the flow rate is sufficiently high, the ex-
periments are feasible. Because the gyromagnetic ratio and
the natural abundance of 1H is much higher than that of 129Xe,
the sensitivity in PHIP experiments may be greater.
As an example, Figure 15b shows 2D RD MR images of HP
propane, which was produced by propene hydrogenation with
para-H2 over an Rh catalyst, flowing in a microfluidic capillar-
y.[230a] Overall, the combined sensitivity gain provided by the
RD scheme and PHIP was 48000-fold, and the experiments
turned out to be one to two orders of magnitude more sensi-
tive than the corresponding RD experiments with HP Xe. Com-
parison of the TOF images of a gas and a liquid (Figures 15b,c)
nicely depicts different flow behavior of these phases; laminar
flow of a liquid translates the encoded liquid molecules over
a large distance (Figure 15c), whereas for a gas the three
orders of magnitude faster diffusion causes efficient mixing of
the flow lamellas, leading to a significantly less dispersed,
plug-like flow behavior (Figure 15b).[230a,b]
Experiments with model microfluidic chips have supported
the viability of the RD-PHIP approach for visualization of com-
plex microfluidic geometries and flow quantification, Fig-
ure 16.[230a] Moreover, these experiments exposed the manufac-
turing imperfections of the chips. The gas flow in different
channels varied in an irregular manner, and the signal ampli-
tude profiles revealed an inhomogeneous distribution of the
gas, implying that the channel depth varied from one channel
to another.
10.2. Microfluidic Reactor Imaging
The natural ability of para-H2 to participate in many important
chemical reactions, including those performed with the use of
microfluidic devices, opens an avenue for studies using HP
gases. Combined RD MRI and PHIP methodologies in such
studies were exemplified by the demonstration of catalytic re-
action imaging of microscale catalyst layers.[230c] Tiny layers of
heterogeneous Rh catalyst packed in thin capillaries (150–
800 mm in diameter) served as model microfluidic reactors. It
was shown that the RD-PHIP methodology can be used for vis-
ualization of mass transport and progress of gas-phase pro-
pene hydrogenation reaction inside the microreactors.
The white dashed rectangles in Figure 17 highlight the loca-
tions of the catalyst layers. The accumulation of produced HP
propane with the distance that gas mixture travels inside the
catalyst layer is visualized by the increased signal amplitude in
the lower part of the reactor. It was shown that under the
given conditions (relatively short travel times), the signal decay
due to nuclear spin relaxation was quite insignificant, and the
amplitude of the HP propane signal was directly proportional
to reaction yield, allowing the determination of the rate of pro-
pene hydrogenation.
In addition, the experiments enabled the observation of gas
adsorption effects in the microfluidic reactors during their in
situ operation, and an elegant approach for quantifying the
Figure 15. a) RD MRI setup of a simplified microfluidic system consisting of
a capillary leading through the encoding and detection coils. TOF RD MRI
visualization of (a) HP propane and b) water flow in the capillary (outlined in
white), revealing much more extensive dispersion of liquid than that of gas
molecules. TOF (ms) is shown at the bottom of the panels. The panels on
the left are sums of the other panels.[230a]
Figure 16. RD MRI of HP propane in microfluidic chips with a) a widened
channel in the middle part and b) ladder-like channels (outlined in white).
These images are the sum of the panels measured at different TOF instan-
ces, and they expose, e.g. , manufacturing imperfections. Flow velocities ex-
tracted from TOF data are shown in b). Reproduced with permission from
Ref. [230a] John Wiley & Sons, Ltd. , 2010.
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amount of absorbed gas using RD NMR was proposed. The au-
thors also introduced the concept of a microfluidic nuclear po-
larizer based on their findings about PHIP produced in the mi-
croscale heterogeneous catalytic hydrogenation.
Further efforts were directed to the development of the con-
cept by employing micro-engineering technologies to produce
micro-structured lab-on-a-chip reactors with the catalyst (sput-
tered Pt) deposited on the inner surface of the channels.[231] It
was found that these reactors did not provide PHIP. However,
these studies provided a platform for further development of
RD NMR for future HP applications, for example, by using Ha-
damard encoding to achieve a better chemical resolution.[231b]
10.3. Outcome and Perspectives
The current advances and future prospects in RD MRI with HP
gases already offer many interesting applications as highlight-
ed above. The major issues concerning the methodology are
related to the availability of HP gases and the lifetime of hy-
perpolarization. HP 129Xe is typically more expensive than the
1H HP hydrocarbon gases produced using PHIP. On the other
hand, the nuclear spin relaxation causes more severe problems
in the case of HP hydrocarbons. Recent developments in the
field of long-lived nuclear spin states,[232] however, may allevi-
ate (or at least mitigate) the latter problem. For instance, it has
been shown that a long-lived HP state in ethylene gas can sur-
vive for ca. 15 min.[233] The further RD NMR development could
concern utilization of such extremely long-lived HP states. In
addition, the progress achieved in the field of single-scan ultra-
fast NMR techniques[234] also offers new capabilities in the con-
text of NMR hyperpolarization. For example, recent work dem-
onstrates the feasibility of single-scan 2D Laplace NMR experi-
ments of dissolved HP propene,[235] and the method should be
applicable, e.g. , for the investigation of dynamics and physical
environments of HP gases in porous media, both with high-
field and low-field (mobile) NMR instruments.[235–236]
11. Conclusion
The development and applications of HP gases continue to ad-
vance, and show no sign of slowing down. In addition to SEOP
hyperpolarization for production of HP 3He and 129Xe, (i) the
SEOP HP technique has been expanded to several other noble
gases, (ii) the heterogeneous PHIP[28a] technique has enabled
production of HP hydrocarbons in pure form (free from con-
tamination by the catalyst), and (iii) the dissolution DNP tech-
nique was demonstrated for production of HP 129Xe[26, 53a] and
15N2O gases.
[237] Thus, many other gases could be potentially
amenable to DNP hyperpolarization.
As a result of these fundamental advances in the physics,
chemistry and engineering of hyperpolarization processes,
which enabled more efficient production of established HP
gases (e.g. , higher throughput and greater polarization in 129Xe
hyperpolarizers)[43i, 238] and other advances that enabled the
production of new HP gases, it was possible to significantly
expand the reach of applications of HP gases in biomedicine
and other fields. For example, as described in this mini-review,
HP 129Xe is now being employed for in vivo thermometry,
brown fat imaging, targeted biosensors, and many other excit-
ing applications, whereas HP hydrocarbons are already used
for high-resolution 3D imaging, remote detection, and micro-
fluidic imaging. Many other new applications will likely emerge
given that HP gases are becoming more available to research-
ers, because hyperpolarization equipment is becoming more
readily available through commercial sources (as opposed to
custom made in the research labs of specialists, as was gener-
ally the case only one decade ago). So far, basic and transla-
tional scientists have been the main driving force behind the
development of MRI of hyperpolarized gases. However, before
their entry into routine clinical practice, further research is
needed to improve image quality and validate its use, qualita-
tively and quantitatively, in respiratory disease. This will un-
doubtedly require collaboration between physicists, chemists
and clinicians. Moreover, the better-established applications
(e.g. , lung imaging using HP 129Xe) will likely continue to be
more fully developed, to the point when studies will be driven
by medical doctors (the ultimate users of this technology)
rather than by the physicists and chemists who pioneered the
technology and helped bring it from the proof-of-principle
stage to the clinical scale. We look forward to all of these de-
velopments with great excitement.
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